Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

From Alzheimer's prevention to weight-loss dominance, Novo bets on innovation and share repurchases amid Medicare pressure.

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts have consistently been hamstrung by manufacturing ...

Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after ... which is their small molecule pill GLP-1, which could really open up the market. So I feel like Novo is kind of losing its pep ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Mounjaro's label notes, however, that the drug is contraindicated in patients with gastroparesis. Novo Nordisk sent pharmaphorum a statement noting that GLP-1 agonists have been used for years to ...